immunotoxicology specialty section newsletter...immunotoxicology specialty section 2...

Immunotoxicology Specialty Section 1

2016-2017Executive Committee

PresidentL. Peyton Myers

Vice PresidentVictor J. Johnson

Vice President-ElectJamie DeWitt

Secretary/TreasurerKristen A. Mitchell

Past PresidentRafael A. PonceSenior Councilor

Haley Neff-LaFordJunior Councilor

Rodney PrellPostdoc Representative

Angela GrovesStudent Representative

Jiajun (Brian) Zhou

The ImTox SS Newsletter is published 3 times/year (Summer, Fall, and Winter). If you would

like to share an item of interest with members of the ImTox SS, please send it to the Communications

Committee Co-Chairs. All comments on, or suggestions to the

newsletter are welcome.

Jiajun (Brian) [email protected]

Angela [email protected].

eduKristen A. Mitchell

[email protected]

Immunotoxicology Specialty Section Newsletter

Summer/Fall 2016 edition

Incoming President’s Message……………………....................................1Outgoing Presidents Message…………………….....................................2Student Postdoctoral Report…………………….......................................4Education Committee Report…………………….....................................4Program Committee Report……………………........................................5ImToxSS Committee Lists……………………............................................6News and Noteworthy.…………………….................................................6ITSS Awards.……………………..................................................................7Job Opportunities……………….…….......................................................11Recent Immunotoxicology Publications……………………...................13

Greetings everyone! I hope your spring and summer have gone well. It seems like only yesterday that we were all down in New Orleans. We would like to thank our speaker Dr. Dawn Wesson (as well as our corporate sponsors, BRT, Burleson Research Technologies, Inc. and Gilead Sciences, Inc.) for the excellent talk on Zika Virus at the ITSS Business Meeting. It was very informative and timely information on Zika Virus. We hope to continue this effort by bringing an exciting speaker to the ITSS Business Meeting in Baltimore and future meetings. As we look forward to the meeting in Baltimore in 2017, I would like to congratulate Vic Johnson and the Program Committee for reviewing, vetting, and ranking multiple submissions. We should also recognize Jeanine Bussiere, our SOT Program Liaison, for her excellent support and advice that helped us streamline some programs and champion our immunotoxicology sessions. It is a hard job to get the programs organized and vetted immediately after the meeting and it looks like the Baltimore meeting will have a strong immunotoxicology program thanks to our ITSS Program Committee. Also, please remember that although the main program session deadline has passed, it is not too late for poster and platform abstracts. The deadline is October 7 on the SOT web site, so mark your calendars. It is also not too early to start planning for the 2018 ITSS program. Along that effort, the ITSS Program Committee is working hard to get an early start in an effort to organize quality sessions in the fall of 2016, prior to the 2017 meeting. While planning future program ideas, please don’t forget to consider possible CE (continuing education) sessions, as the SOT Program Committee is especially interested in seeing CE proposals from ITSS. This will help the new Program chair (as well as the committee) to vet potential ideas in the fall, when we are less rushed after the SOT Annual Meeting. Please contact Jamie DeWitt

Incoming President’s Message


([email protected]) and Vic Johnson ([email protected]) if you have any ideas for sessions for 2018. Along those lines, we would like to announce a new partnership with ILSI/HESI to help increase opportunities for immunotoxicology education and/or collaboration throughout the year. In the past, there have been many outside Immunotoxicology sessions organized by various entities dating back to the Medical College of Virginia. To help continue this effort of having a session organized specifically for immunotoxicology peers to meet and discuss issues, ILSI/HESI has offered to partner with the SOT ITSS to help organize a session for 2017. The session is still in its infancy but it likely will be a two day event and will be planned not to conflict with any of the other major society events in the Spring. We will keep you updated as the ILSI/HESI session develops. I hope everyone has a great Fall and I look forward to seeing you in Baltimore.

Incomingpresident’s

messageOutgoing

president’s message

Dr. Rafael PoncePass president, ITSS 2015-2016

As outgoing president of the Immunotoxicology Specialty Section, I would like to express my gratitude for the wonderful membership, Executive Committee and SOT staff who make this a tremendous and vibrant Specialty Section. We are consistently among the most highly visible components of the Annual Meeting, with cross-disciplinary and collaborative research as a hallmark of our efforts. Over the last year, we have taken steps to ensure we remain attuned to the needs of our membership. We continue to support and encourage mentorship of our younger scientists, and we are evolving efforts that reach beyond the Annual Meeting. In addition, to ensure we support and guide our scientists to reach their highest potential we are taking steps to build an intensive workshop in collaboration with ILSI/HESI so as to provide current insights into basic immunology and case studies focusing on specific areas of immunotoxicology. This year’s Executive Committee is exceptional, and I am eager to see their new efforts to facilitate an engaged and vibrant membership! We encourage you to get involved. Feel free to reach out to members of the Executive Committee – whether you want to volunteer as a member of the Executive Committee or one of several sub-committees, focus on mentorship, participate in the workshops, or have other ideas - we welcome your involvement.

Submitted by Rafael Ponce

Dr. Laine Peyton MyersPresident, ITSS 2016 - 2017


Dear graduate student and postdoctoral members of ITSS, I hope you have had a wonderful and productive summer. I would like to thank everyone that participated in the student/postdoc mixer and the 2nd Annual Networking Event hosted by the Immunotox Specialty Section for graduate students and postdoctoral members. We had around 20 students/postdocs participate in this event. The participants had the opportunity to interact with diverse panelists from academia, industry and government and learn how these panelists started their careers and how they achieved their positions. We received positive feedback from the participants about the event, and most participants indicated they would attend the event again in the future. More than half of the participants were non-ITSS members, which indicates that the event was well advertised and fulfilled a similar event was not found at SOT. Please stay tuned for more information coming soon regarding for the 3rd Annual ITSS Networking Event to be held next year at the 56th SOT Annual Meeting at Baltimore, Maryland. We would like to encourage new students and postdocs to engage in the ITSS by volunteering for a committee of your interest. These activities can help you connect with fellow immunotoxicologists and gain valuable experience.

Submitted by Jiajun(Brian) Zhou and Angela Groves

Student

Report&Postdoc

EducationCommittee

Report

Over the past two years, the ITSS Education Committee has hosted a mentoring event for students and postdocs. At this mentoring event, students and postdocs have the opportunity to casually engage with toxicological professionals from academia, government, and industry whose primary focus is immunotoxicology. For two years in a row, this event has been a phenomenal success. In fact, it might be a little too successful as a common suggestion of attendees is to increase the number of mentors and the time they are able to spend with mentors. And so, this brings us to the punchline…volunteer! If you happen to receive one of the coveted email invitations from an ITSS Education Committee member to be a mentor, say yes! Being invited means that you were nominated for your positive influence on someone’s professional development (and no, if you weren’t nominated it doesn’t mean that you were a horrible influence). As this year progresses and we approach the 2017 national meeting, keep on the lookout for information about the mentoring event. In addition, the Education Committee will be working to offer an educational meeting in conjunction with ILSI/HESI. Again, keep on the lookout for ITSS Education Committee information.

English? Who needs that? I’m never going to England. Wise words from Homer Simpson

Jamie DeWitt, Chair


ProgramCommittee

Report

Each April, members of the ITSS Program Committee literally freak out. SOT gives members until the end of April to submit program proposals for consideration at the next year’s national meeting. Most of these proposals fare better if endorsed by one or more Specialty Sections, which means they need to be submitted to Specialty Sections in mid-April to attain feedback and an endorsement. However, up until mid-March, most of us are thinking of the current year’s national meeting and barely begin to think about the next year until bombarded by urgent pleas from specialty section Program Committees. Let’s stop freaking out!

The SOT Program Committee has indicated a need for a Continuing Education course based on Immunotoxicology. Start putting together this proposal now and submit it to the ITSS Program Committee chair before the 2017 Annual meeting!

Did you have an absolutely fantastic idea for the 2017 meeting but missed the deadline? Put together a proposal and submit it to the ITSS Program Committee chair before the 2017 annual meeting! Don’t wait until the last minute. Don’t let your ideas get lost in the time crunch. Don’t make the Program Committee scramble at the last minute. We look forward to receiving proposals throughout the year so that they can be submitted at the start, rather than the end of the submission period.

In upcoming newsletters, we will direct you to resources to help you to put together a competitive proposal. SOT has information to help you to plan and submit proposals at http://www.toxicology.org/events/am/sciProgram.asp. They also hold webinars and sessions at the national meeting. Take advantage of these and stop freaking out!

The following is a recap of the adventures of the 2016-2017 ITSS Program Committee: We are expecting that all of the proposals that were tentatively accepted will result in final acceptance for presentation at the 2017 meeting in Baltimore. An update including session titles will be provided in a future newsletter once the

SOT Program Committee make final decisions on acceptance.

We had an excellent push last April that resulted in 16 quality proposals being submitted to ITSS for review and endorsement. Great work! Let’s build on that for 2018.

Proposal submissions: 16 total• Workshop: 3 proposals submitted; 2 proposals tentatively accepted for 2017 meeting• Symposium: 11 proposals submitted; 5 proposals tentatively accepted for 2017 meeting• CE Course: 2 proposals submitted; 0 proposals accepted

It’s never too early to think about proposals for SOT 2018!

Vic Johnson, Chair


ProgramCommittee

ReportProposal acceptance for SOT 2017

Exiting news !!!

Symposium Lifespan Neuroimmunotoxicology: Age-Dependent Neuroimmune Dyshomeostasis Caused by Pollutants, Pathogens and Psychoactive Substances (Chairs: Nick Filipov, University of Georgia; Vic Johnson, Burleson Research Technologies) March 13, 2017 2:00pm - 4:45pm

Workshop Bispecific Molecules: Nonclinical and Clinical Development Challenges (Chairs: Pedro Del Valle, US FDA; Patricia Ryan, MedImmune, LLC) March 13, 2017 2:00pm - 4:45pm

Symposium Chemically Induced Neuroinflammation and “Sickness Behavior” Disorders (Chairs: G. Jean Harry, NIEHS/NIH; James O’Callaghan, CDC-NIOSH) March 14, 2017 2:00pm - 4:45pm

Symposium Emerging Concepts in Nonclinical Development of Immuno-Oncology Agents: Enabling Translation of Non-clinical Pharmacology and Safety Information to First-in-Human Clinical Trials (Chairs: Vijayapal Reddy, Eli Lilly and Company; Jacqueline Kinyamu‐Akunda, Novartis Institute for Biomedi-cal Research) March 14, 2017 2:00pm - 4:45pm

Symposium Enhancing the Clinical Benefit of Cancer Drugs: Toxicity As a Therapeutic Target (Chairs: Syril Pettit, HESI; Brian Berridge, GlaxoSmithKline) March 15, 2017 2:00pm - 4:45pm

Symposium The Skin As A Metabolic And Immune-Competent Organ: Implications for Pharmaceutical Development and Safety Assessment (Chairs: Yoshiro Saito, MHLW Japan; Jeanine Bussiere, Amgen, Inc.) March 15, 2017 9:30am - 12:15pm

Workshop Biological Advances to Help Navigate the Nonclinical Safety Assessment Strategy in Cancer Immunotherapy: Utility, Limitations, and Future Direction (Chairs: Robert Li, Genentech; Jacintha Shenton, Janssen) March 16, 2017 8:30am - 11:15pm


International Exchange

The Immunotoxicology Specialty Section (ITSS) of the Society of Toxicology (SOT) and the Japanese Society of Immunotoxicology (JSIT) have a longstanding partnership fostering international exchange of science in the field of Immunotoxicology. The year 2016 marks the 11th anniversary of the joint ITSS-JSIT International Exchange Committee and the sharing of cutting edge science in Immunotoxicology between the two societies. The 23rd Annual Meeting of the Japanese Society of Immunotoxicology was held on Sept. 5-7, 2016 at the Kitakyushu International Conference Center in Kokurakita-ku, Fukuoka, Japan. The meeting theme was “Immunotoxicology and Translation to Society and Health Practice” with particular reference to health risk assessment of nanoparticles. I had the privilege of being the ITSS delegate invited to attend the JSIT meeting. It was a great honor for me to present the Special Keynote Lecture “Inhaled Nanoparticles: Consequences of Exposure and Approaches for Hazard Identification”.The JSIT meeting was filled with cutting-edge immunotoxicology presentations from the JSIT membership; this included many oral presentations and Master Lectures from senior scientists and oral/poster presentation from students and young scientists in Immunotoxicology. The JSIT also organized two luncheon seminars with that highlighted presentations from non-JSIT members including Lee Coney (Envigo CRS, Ltd.) and Vanessa Peachee (Charles River Labs). It was great to observe the engagement of the membership in each and every presentation. In all the lectures that I was able to attend, questions from the audience could have gone on at length, but were held to a timeline to keep the schedule on track. This demonstrates the enthusiasm and scientific interest in Immunotoxicology in Japan. While attending the meeting, time was devoted to discussions with members of the JSIT Executive Board and general membership regarding the ITSS-JSIT partnership and how to foster communication and outreach between the societies. There was a general consensus that the exchange of articles for publication in the ITSS and JSIT newsletters represents one excellent mechanism to exchange ideas and highlight hot topics in the international Immunotoxicology community on an ongoing basis. This concept has been proposed to the ITSS Executive board and was very well received

with unanimous support. The Communications Committees of both societies will maintain contact to encourage submissions and to inform of publication deadlines. Look for these articles in future ITSS (https://www.toxicology.org/groups/ss/imtox/newsletter .asp) and JSIT (http://www.immunotox.org/english/immunotoxletter/index.html) newsletters. The International Exchange Committee (IEC) works with members of ITSS and JSIT to foster program ideas for submission to SOT for consideration for the following year’s annual meeting. This year, JSIT identified Dr. Yoshiro Saito as their representative. Dr. Saito partnered with Dr. Jeanine Bussiere (ITSS member) to develop an immunotoxicology-focused proposal for submission to SOT for our 2017 Baltimore meeting. On behalf of the ITSS, I would like to congratulate Yoshiro and Jeanine on the acceptance of their proposal for presentation at the 2017 meeting. Thanks for the hard work; we all look forward to learning more about the role of skin metabolism and immunology and its role in drug development and safety assessment. The symposium “The Skin As A Metabolic And Immune-Competent Organ: Implications for Pharmaceutical Development and Safety Assessment” and will be presented from 9:30 AM-12:15 PM on March 15, 2017. Looking forward to a great session! On a more personal note, this was my first experience traveling to Japan and the idea was a little bit intimidating. However, the hospitality of JSIT dissolved that feeling and made me very comfortable and confident in my travels. I would like to thank Dr. Yasuo Morimoto (Chair of the JSIT meeting) and the JSIT membership for making my stay very enjoyable and for the enthusiasm expressed from the JSIT membership following my lecture. A special thank you goes Alice Kayama for her excellent tour of the Kokura area. My trip to Japan was made perfect by the gracious efforts of Drs. Masashi Tsunoda and Fujio Kayama, colleagues and great friends, for their planning and hospitality for the days after the meeting prior to returning home. Masashi, your education on Japanese culture and tradition while visiting many of the Japanese National Treasures was priceless. Fujio, thank you for the wonderful beverages and meal in Tokyo! I am forever grateful for this experience.

International Exchange in Immunotoxicology: ITSS – JSIT Partnership

Vic Johnson


Immunotoxicology Specialty Section Committee Lists – 2016/2017

Awards Committee:Haley Neff-LaFord, Chair

Marpe Bam

We need your help!!!Please volunteer for the Award Committee.

Program Committee:Vic Johnson, Chair

Marpe BamWillian Becker

Saurabh ChatterjeeJamie DeWitt

M. Firoze KhanLaine Meyers

Rochelle MikkelsenAshwini Phadnis-Moghe

Berran YucesoyBrian Zhou

Education Committee:Jamie DeWitt, Chair

Cheryl RockwellYu Feng

Aimee HillegasBassam KashgariAshwini PhadnisSusan McKarns

Alex TurleyJoe Zagorski

Communications & Membership Committee:Kristen MitchellAngela Groves

Jiajun (Brian) Zhou

If you would like to join a committee, there are still openings on the Communications & Membership and Education Committees.

Please contact the ITSS Secretary/Treasurer or the Chairperson of the committee(s) if you are interested in joining.

Exciting

Saurabh Chatterjee, Ph.D. was promoted to Associate Professor of Cell Biology and Anatomy with tenure at the University of South Carolina, De-partment of Environmental Health Sciences, School of Medicine. He would like to thank his peers and ITSS members for their continuous support and encouragement.

News


Vos Award for Lifetime Career Achievement in Immunotoxicology

The Vos Award for Lifetime Career Achievement in Immunotoxicology is presented to an individual in recog-nition of career achievements in advancing the field of immunotoxicology through service, leadership, and scientific contributions. This year’s honoree was Dr. Prakash Nagarkatti from University of South Carolina.

ITSSAwards

Outstanding Senior Investigator AwardThe Outstanding Senior Investigator Award

is presented to an individual whose work has made significant

contributions to the field of Immunotoxicology. This award is for scientists in academia, industry, or those who have had an impact on regulatory issues, and has distinguished themselves as leaders in their chosen

area of immunotoxicology.

Dr. Marc PallardyUniversité de Paris

Nominated by: Dr. Jack DeanDr. Hervé Lebrec

Dr. Prakash NagarkattiVice President for Research, Carolina Distinguished ProfessorUniversity of South Carolina


ITSSAwards

Outstanding Young Investigator Award

Health and Environmental Sciences Institute (HESI) Immunotoxicology Young Investigator Travel Award

The Outstanding Young Investigator Award is presented to an individual whose work has made significant contributions to the field of Immunotoxicology. This award is for scien-tists in academia, industry, or those who have had an impact on regulatory issues, having 10 years or less of experience since obtaining their highest degree.

Dr. Kymberly GowdyEast Carolina University

Nominated by: Dr. Jamie Dewitt

Dr. Angela GrovesUniversity of Rochester

Differing Pulmonary Immune Responses Following Exposure to Thoracic Radiation in Fibrosis Sensitive and Resistant Mice

Angela Groves, Ravi Misra, Carl Johnston, Tyler Beach, Jackie Williams, Jacob Finkelstein

Nominated by: Jacob N. Finkelstein, Ph.D


ITSSAwards

Best Paper of the Year 2015

Best Presentation by a Postdoctoral Trainee Award

Linking the aryl hydrocarbon receptor with altered DNA methylation patterns and developmentally induced aberrant antiviral CD8+ T cell responsesJ. Immunol. 1402044; published ahead of print March 25, 2015

Bethany Winans, Anusha Nagari, Minho Chae, Christina M. Post, Chia-I Ko, Alvaro Puga, W. Lee Kraus and B. Paige Lawrence. University of Rochester

Long-term Effects of Early-life Arsenic Exposure on Innate Immunity

Fenna C.M. Sillé, Sylvia S. Sanchez, Daniel A. Medina-Cleghorn, Daniel K. Nomura, Craig M. Steinmaus, Allan H. Smith, Martyn T. Smith.

Dr. Fenna SilléUniversity of California BerkleyNominated by: Dr. Martyn T. Smith


ITSSAwards

Best Presentation by a Student Award

Joanna KreitingerUniversity of Montana

Aryl Hydrocarbon Receptor Activation in CD11c+ Cells Mediates Effects of TCDD on T

Lymphocyte Development in the Thymus

Nominated by: Dr. David Shepherd

First Place

Alexandra E. TurleyMichigan State University

Nrf2 Promotes Th2 Differentiation in Murine and Human CD4 T Cells

Nominated by: Dr. Cheryl Rockwell

Third Place

Jinpeng LiMichigan State University

TCDD-Mediated Alterations of EBF1 in Im-paired Early Human B Cell Development

Nominated by: Dr. Norbert Kaminski

Natalia KovalovaMichigan State University

Role of Aryl Hydrocarbon Receptor (AhR) Polymorphisms in TCDD-Mediated Biological

Activity in the Human B Cell

Nominated by: Dr. Norbert Kaminski


Job Opportunities

Investigative Toxicologist – Nonclinical DevelopmentNGM Biopharmaceuticals, Inc. is a private, maturing biotech start-up dedicated to discovering the next gen-eration medicines to treat grave diseases. Our experienced scientific team has joined forces with an impres-sive group of industry professionals, Nobel Laureates, and other distinguished researchers to form a company where innovation and cutting edge science will provide the foundation for a robust drug discovery engine. In 2015, we established a broad collaboration with Merck that will provide us with the resources and flexibility to pursue our ambitious research and development goals. This partnership is a strong validation for NGM as a biologics discovery engine that will generate transformational medicines for unmet medical needs.Responsibilities:

• Determine and evaluate potential safety and toxicity liabilities of biologic pathways of interest to sup-port drug discovery and development. • Design, plan, monitor, conduct and report preclinical toxicology studies to support drug candidate nomination and early preclinical drug development activities.• Contribute to the understanding of the relevance of nonclinical safety findings to humans and lead the design and conduct of experiments to help inform their potential translatability. • Develop and conduct in vitro assays as appropriate for novel safety biomarker evaluation• Contribute to the design, monitoring and reporting of nonclinical IND-enabling GLP toxicology stud-ies• Manage nonclinical development studies in-house and at contract research organizations• Support nonclinical pharmacology and efficacy studies as they relate to assessment of PKPD

Education:• PhD degree in toxicology, pathology, pharmacology, or related discipline• Post doctoral experience preferred

Requirements:• Minimum 1-3 years experience in the biotech/pharmaceutical industry in the area of nonclinical drug discovery and/or development. • Strong research background with proven ability to contribute to the understanding of the pharmaco-logic/toxicologic mechanism(s) of drug-induced responses in animals.• Ability to immerse in the understanding of complex biologic pathways across multiple programs and identify key research activities of importance• Must be detail oriented with strong documentation and organizational skills

Additional Requirements:• Excellent interpersonal skills, ability to work in a matrix environment and develop relationships with key stakeholders. • Excellent communication and presentation skills to efficiently relay information to project teams and other key stakeholders• Experience with large molecule (proteins and monoclonal antibody) drug discovery and development desired, but not required• Proven ability to work independently and be self-motivated

NGM offers a creative, collaborative, highly challenging scientific environment, along with a strong compen-sation package that includes salary, stock options, 401(k) and a comprehensive benefits package.Interested applicants should apply through the NGM Biopharmaceuticals website: http://www.ngmbio.com/careers/#SilkroadFrame

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commer-cializes innovative medicines in areas of unmet medical need. With each new discovery and investigational drug candidate, we seek to improve the care of patients living with life-threatening diseases around the world. Gilead’s therapeutic areas of focus include HIV/AIDS, liver diseases, serious respiratory and cardiovascular


conditions, cancer and inflammation, headquartered in Foster City, California. Job Title: Sr Research Scientist I, (Requisition # 23886)Job Type: Regular, Full-TimeLocation: Foster City, CA Specific Responsibilities and Skills for Position: Manages multiple projects within the functional area simultaneously with minimal supervision § May serve as core team member on Development teams, and as DSE representative on Development sub teams and Re-search Teams § Advanced knowledge and expertise in diverse areas within the discipline area; working knowl-edge of other relevant disciplines inside and/or outside of toxicology § Oversees the procedural and scientific aspects of studies throughout the duration of a drug development program § Utilizes understanding of broad strategy and assist in devising novel solutions to scientific and portfolio issues § Develops strong working relationships with internal and external groups § Independently designs and conducts non-clinical studies to support research and development projects and applies appropriate regulatory requirements § Leads protocol review discussions concerning scientific and procedural aspects of study design § Monitors and coordinates all aspects of moderately to highly complex outsourced studies independently § Interprets complex study data and communicates findings § Develops innovative solutions to complex technical problems using broad knowledge of toxicology/pathology and scientific literature. § Prepares and reviews regulatory documents § Develops recognized expertise in selected area. Essential Functions: Knowledge of GLPs, ICH Guidelines and other regional requirements and nonclinical drug discovery and de-velopment • Ability to work independently within a fast-paced, demanding, performance-oriented and “results driven” environment • Excellent self-management and organizational skills, able to manage work load • Ability to work effectively with cross-functional teams in a matrixed environment • Clear and concise oral and written communication skills • Strong computer skills • Travel is required Knowledge, Experience and Skills: PhD or DVM in pharmacology, toxicology, or related scientific discipline and 6+ years of experience in small molecule and/or biopharmaceutical drug development, board certification desirable, but not required • Expe-rience in the design and interpretation of nonclinical GLP and non-GLP investigative studies to enable clinical development and candidate registration globally As an equal opportunity employer, Gilead Sciences Inc. is committed to a diverse workforce. In order to ensure reasonable accommodation for individuals protected by Section 503 of the Rehabilitation Act of 1973, the Vietnam Era Veterans’ Readjustment Act of 1974, and Title I of the Americans with Disabilities Act of 1990, applicants who require accommodation in the job application process may contact [email protected] for assistance. For more information about equal employment opportunity protections, please view the EEO is the Law poster. Please contact Debbie Nishijima, Gilead Talent Acquisition, (650)-522-1124 or [email protected] for more information.

Job Opportunities


RecentImmunotoxicology

PublicationsCompiled by Angela Groves. Anytime you have a new fully-published or electronically-available article to report, please send the citation to Angela at [email protected].

Asthma, Allergy, Autoimmunity & HypersensitivityAnderson, S.E., Meade, B.J., Long, C.M., Lukomska, E. and Marshall, N.B., 2016. Investigations of immuno-toxicity and allergic potential induced by topical application of triclosan in mice. Journal of immunotoxicolo-gy, 13(2), pp.165-172.

Anderson, S.E., Shane, H., Long, C., Lukomska, E., Meade, B.J. and Marshall, N.B., 2016. Evaluation of the irritancy and hypersensitivity potential following topical application of didecyldimethylammonium chloride.Journal of immunotoxicology, pp.1-10.

Basketter, D.A. and Kimber, I., 2016. Phthalic anhydride: Illustrating a conundrum in chemical allergy. Jour-nal of immunotoxicology, pp.1-3.

Hansen, J.S., Nørgaard, A.W., Koponen, I.K., Sørli, J.B., Paidi, M.D., Hansen, S.W., Clausen, P.A., Nielsen, G.D., Wolkoff, P. and Larsen, S.T., 2016. Limonene and its ozone-initiated reaction products attenuate allergic lung inflammation in mice. Journal of Immunotoxicology, pp.1-11.

Joshi, S.S., Barnett, B., Doerrer, N.G., Glenn, K., Herman, R.A., Herouet-Guicheney, C., Hunst, P., Kough, J., Ladics, G.S., McClain, S. and Papineni, S., 2016. Assessment of potential adjuvanticity of Cry proteins.Regu-latory Toxicology and Pharmacology, 79, pp.149-155.

Martinez-Gonzalez, I., Mathä, L., Steer, C.A., Ghaedi, M., Poon, G.F. and Takei, F., 2016. Allergen-Experi-enced Group 2 Innate Lymphoid Cells Acquire Memory-like Properties and Enhance Allergic Lung Inflam-mation.Immunity, 45(1), pp.198-208 Developmental ImmunotoxicologyJusko, T.A., De Roos, A.J., Lee, S.Y., Thevenet-Morrison, K., Schwartz, S.M., Verner, M.A., Murinova, L.P., Drobná, B., Kocˇan, A., Fabisiková, A. and Cˇonka, K., 2016. A birth cohort study of maternal and infant serum PCB-153 and DDE concentrations and responses to infant tuberculosis vaccination. Environmental Health Perspectives (Online), 124(6), p.813.

Oulhote, Y., Shamim, Z., Kielsen, K., Weihe, P., Grandjean, P., Ryder, L.P. and Heilmann, C., 2016. Children’s white blood cell counts in relation to developmental exposures to methylmercury and persistent organic pollutants. Reproductive Toxicology.

Sans, J.D.P., Clements, K.J., Suvorov, A., Krishnan, S., Adams, H.L. and Petersen, S.L., 2016. Developmental exposure to 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin may alter LH release patterns by abolishing sex differences in GABA/glutamate cell number and modifying the transcriptome of the male anteroventral periventricular nucleus. Neuroscience, 329, pp.239-253.

General ImmunotoxicologyAnetor, J.I., Uche, C.Z., Ayita, E.B., Adedapo, S.K., Adeleye, J.O., Anetor, G.O. and Akinlade, S.K., 2016. Cadmium level, glycemic control, and iIndices of renal function in treated type II diabetics: implications for polluted environments. Frontiers in Public Health, 4, p.114.



PublicationsGeneral Immunotoxicology ContunuedFrawley, R.P., Smith, M.J., White Jr, K.L., Elmore, S.A., Herbert, R., Moore, R., Staska, L.M., Behl, M., Hooth, M.J., Kissling, G.E. and Germolec, D.R., 2016. Immunotoxic effects of sodium tungstate dihydrate on female B6C3F1/N mice when administered in drinking water. Journal of Immunotoxicology, pp.1-10.

Fu, J., Shi, Q., Song, X., Liu, Z., Wang, Y., Wang, Y., Song, E. and Song, Y., 2016. Tetrachlorobenzoquinone exerts neurological pro-inflammatory activity by promoting HMGB1 release, which induces TLR4 clustering within the lipid raft. Toxicological Sciences, p.kfw124.

Gilmer, J., Serve, K., Davis, C., Anthony, M., Hanson, R., Harding, T. and Pfau, J.C., 2016. Libby amphibole-in-duced mesothelial cell autoantibodies promote collagen deposition in mice. American Journal of Physiolo-gy-Lung Cellular and Molecular Physiology, 310(11), pp.L1071-L1077.

Imani, S., Salimian, J., Fu, J., Ghanei, M. and Panahi, Y., 2016. Th17/Treg-related cytokine imbalance in sulfur mustard exposed and stable chronic obstructive pulmonary (COPD) patients: correlation with disease activity.Immunopharmacology and immunotoxicology, pp.1-11.

Hanson, R., Evilia, C., Gilmer, J., Woods, L., Black, B., Flores, R., Pfau, J.C. 2016. Libby Amphibole-Induced Anti-Mesothelial Cell Autoantibodies Bind to Surface Plasminogen and Alter Collagen Matrix Remodeling. In Press: Physiological Reports

Kitazawa, M., Hsu, H.W. and Medeiros, R., 2016. Copper exposure perturbs brain inflammatory responses and impairs clearance of amyloid-beta.Toxicological Sciences, p.kfw081.

Matsuzaki, H., Lee, S., Maeda, M., Kumagai-Takei, N., Nishimura, Y. and Otsuki, T., 2016. FoxO1 regulates apoptosis induced by asbestos in the MT-2 human T-cell line. Journal of immunotoxicology, pp.1-8.

Pedata, P., Petrarca, C., Garzillo, E.M. and Di Gioacchino, M., 2015. Immunotoxicological impact of occupa-tional and environmental nanoparticles exposure: The influence of physical, chemical, and combined charac-teristics of the particles. International journal of immunopathology and pharmacology, p.0394632015608933.

Ratajczak, H.V. and Sothern, R.B., 2015. Measurement in saliva from neurotypical adults of biomarkers perti-nent to autism spectrum disorders.Future Science OA, 1(4).

Ratanji, K.D., Dearman, R.J., Kimber, I., Thorpe, R., Wadhwa, M. and Derrick, J.P., 2016. Subvisible aggregates of immunogenic proteins promote a Th1-type response. Toxicological Sciences, p.kfw121.

Unnisa, Z., Singh, K.P., Henry, E.C., Donegan, C.L., Bennett, J.A. and Gasiewicz, T.A., 2016. Aryl Hydrocarbon Receptor Deficiency in an Exon 3 Deletion Mouse Model Promotes Hematopoietic Stem Cell Proliferation and Impacts Endosteal Niche Cells. Stem Cells International, 2016.

Vogel, C.F., Chang, W.L., Kado, S., McCulloh, K., Vogel, H., Wu, D., Haarmann-Stemmann, T., Yang, G., Leung, P.S., Matsumura, F. and Gershwin, M.E., 2016. Transgenic Overexpression of Aryl Hydrocarbon Recep-tor Repressor (AhRR) and AhR-Mediated Induction of CYP1A1, Cytokines, and Acute Toxicity. Environmen-tal health perspectives.



PublicationsYucesoy, B., Talzhanov, Y., Barmada, M.M., Johnson, V.J., Kashon, M.L., Baron, E., Wilson, N.W., Frye, B., Wang, W., Fluharty, K. and Gharib, R., 2016. Genetic Basis of Irritant Susceptibility in Health Care Workers. Journal of occupational and environmental medicine/American College of Occupational and Environmental Medicine.

Yucesoy, B., Talzhanov, Y., Michael Barmada, M., Johnson, V.J., Baron, E., Wilson, N.W., Frye, B., Wang, W., Fluharty, K. and Gharib, R., 2016. Association of MHC region SNPs with irritant susceptibility in healthcare workers. Journal of immunotoxicology, pp.1-7.

Methods/ModelsLiu, F., Cai, P., Metushi, I., Li, J., Nakayawa, T., Vega, L. and Uetrecht, J., 2016. Exploring an animal model of amodiaquine-induced liver injury in rats and mice. Journal of Immunotoxicology, pp.1-19.

Sominski, D.D., Rafferty, P., Brosnan, K., Volk, A., Walker, M., Capaldi, D., Emmell, E., Johnson, K. and Wein-stock, D., 2016. Development of a squamous cell carcinoma mouse model for immunotoxicity testing. Journal of immunotoxicology, 13(2), pp.226-234.

Lapointe, J.M., Valdez, R.A., Ryan, A.M. and Haley, P.J., 2016. Evaluation of the utility of popliteal lymph node examination in a cyclophosphamide model of immunotoxicity in the rat. Journal of immunotoxicology, pp.1-4.

Reviews/Books/CommentariesWill, Y., McDuffie, J.E., Olaharski, A.J. and Jeffy, B.D. eds., 2016. Drug Discovery Toxicology: From Target Assessment to Translational Biomarkers. John Wiley & Sons.

Burchiel, S.W. and Gao, J., 2016. Polycyclic Aromatic Hydrocarbons and the Immune System. Encyclopedia of Immunotoxicology, pp.710-715.

Announcement

Abstract Submission: October 7, 2016Award Nominations: October 9, 2016

immunotoxicology specialty section newsletter...immunotoxicology specialty section 2...

Documents